Home » Topics » Regulatory » EMA

EMA
RSS

Shire's Adynovi receives positive opinion in E.U.

Nov. 14, 2017

EMA recommends Prevymis for marketing authorization

Nov. 14, 2017

EMA grants positive opinion for Ocrevus as treatment for patients with RMS or PPMS

Nov. 14, 2017

EMA grants PRIME designation to Mereo's BPS-804

Nov. 13, 2017

EMA committee confirms refusal of Fanaptum MAA

Nov. 13, 2017

Benralizumab obtains positive opinion in E.U.

Nov. 13, 2017

CHMP issues positive opinion on Avastin biosimilar ABP-215

Nov. 13, 2017

EMA committee recommends expanding approval of Orkambi

Nov. 13, 2017

EMA's CHMP supports expanding Nplate indication

Nov. 13, 2017

FDA gives orphan status to Achillion's ACH-4471 for PNH

Nov. 8, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...